enreach glp-1 Receptor Agonists: The New Wave in Diabetes Management Join us for an As the prebiotics are #CleanIngredients Purchase Plan:3-Months Supply

enreach glp-1 Receptor Agonists: The New Wave in Diabetes Management Join us for an As the prebiotics are #CleanIngredients Purchase Plan:3-Months Supply

Join us for an encore presentation TONIGHT of On Call with the Prairie Doc® as we dive into the science of weight loss. Are you looking for sustainable, evidence-based approaches to weight

Liraglutide, semaglutide and tirzepatide are European Medicines Agency approved to improve metabolic control in T2DM and to decrease weight in persons with obesity [body mass index (BMI) ≥30 kg/m 2 ] or with overweight (BMI ≥27 kg/m 2 ) associated with weight-related comorbidities such as hypertension, dyslipidaemia, CVD and others

#CleanIngredients

Purchase Plan:3-Months Supply

Of the 81 ION incidences that occurred among GLP-1 users, 85.2% were in people aged 50 years or older and 70.3% were in men “despite females comprising the majority of GLP-1 receptor agonist initiators overall (55%),” Reynolds and colleagues noted

As the prebiotics are fermented within the gut they help fuel natural GLP